April 29th 2025
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
April 28th 2025
The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.
April 24th 2025
The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.
April 15th 2025
One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.
A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.
Here comes the 21st Century Cures Act
Bills passes House with broad bipartisan support; Senate approval likely
PCMA survey: consumers blame pharma for high prices and high OOP
A counterargument to the belief that out-of-pocket expenses originate with insurers or PBMs
Patheon picks up a Roche facility in South Carolina
Sale comes with multi-year supply agreement
Catalent adds to softgel capacity with proposed acquisition of Accucaps
Two Canadian Accucaps facilities join global network of 11 Catalent RP Scherer Softgel locations
Life sciences is a good recycler of real estate
Allergan’s big commitment to NJ; U. of Michigan converts pharma facilities to healthcare and education
Former Valeant and Philidor executives arrested by DoJ
Upcoming trial could explore the intricacies of ‘alternative fulfillment’ via specialty pharmacies
EzriRx seeks to consolidate pharma purchases for independent pharmacies
An Amazon-like model for creating an open market for wholesalers to reach customers
A conversation with Jim Mullen, Patheon
Turning up the heat on PBM’s role in drug pricing
Will employer benefit plans lose their enthusiasm for PBMs?
AmerisourceBergen quarterly results: what industry downturn?
Revenues and earnings were up for the year; stock jumps 8.8% in the day
Winter is coming sooner for Big Three wholesalers
McKesson disappoints on Q2 earnings call; stock drops 23%. Update: Cardinal reports more revenue, less profit
GPhA: generics saved $227 billion in drug costs in 2015
Price growth is less than branded growth, but higher than inflation
More trouble for Mylan over EpiPen pricing and rebates [updated]
Company may have erroneously been operating under a generic classification
Quintiles / IMS Health merger is complete
New company is to be known as QuintilesIMS
Retail clinics are on a 26%/year growth trajectory, says Kalorama
Drug dispensing, point of care testing and diagnostics are beneficiaries
Avella Specialty Pharmacy tops list of fast-growing private pharmacies
Drug Channel’s analysis of Inc. 5000 shows some eye-popping growth
Deloitte unveils ExaLink, a cloud-based commercial-compliance portal
CIS by Deloitte seeks to provide a comprehensive service for revenue management
Much heat, little new light in Mylan’s Congressional hearing over EpiPen pricing
Mylan CEO sticks to authorized-generic strategy for price relief
Global pharma market will reach $1.12 trillion in 2022
Roche could overtake Novartis as the No. 1 global firm by then, says Evaluate Pharma
Drug pricing brawl turns to PBMs
Pharmacy benefit managers feel some marketplace heat even as they establish new benefit programs
Walgreens Boots Alliance continues its consolidation of pharma distribution
Walgreens-Rite Aid merger is still pending
When is a branded drug a generic? When it is sold by Mylan…
EpiPen controversy has a new twist: paying lower rebates to state Medicaid programs
A conversation with Gerry Gleeson, Walgreens Specialty Pharmacy
Moving From Big Pharma To A Small Company? You May Be In For A Few Surprises
Sponsored by TGaS Advisors
Mylan’s EpiPen re-energizes drug pricing disputes
Presidential politicking adds momentum to the growing backlash, and not just for Mylan
Where are those missing billions in new-product pharma sales?
Healthcare research firm calls out the alarmist predictions over PCSK9s and other new drugs
PPD snaps up Evidera, deepening services in real-world evidence
CROs are expanding their scope of services
Generics distributor Anda, Inc. has a new owner: Teva Pharma
Deal deepens Teva’s business in generics
Private-capital injection into inVentiv Health reshuffles life sciences outsourcing
Advent joins Thomas Lee Partners in ownership of the clinical, commercial outsourcer
Preparing for a cell culturing industry
GE Healthcare makes a key acquisition in cell culture production technology